Vera Therapeutics, Inc. · NASDAQ:VERA
Vera Therapeutics — Investor Presentation (November 2025)
6 slides from Vera Therapeutics's investor presentation, Nov 6, 2025
Slide 1: Corporate Presentation November 6, 2025
Corporate Presentation November 6, 2025 Exhibit 99.1
Slide 2: Primary Endpoint: UPCR Reduction
Primary Endpoint: UPCR Reduction Interim Analysis Set (IAS) included the first 203 randomized participants who received ≥1 dose of trial drug. Change from baseline in natural-log transformed UPCR at Week 36 was analyzed using a mixed-effects model with repeated measurement (MMRM), including fixed ef
Slide 3: UPCR Efficacy Consistent Across Prespecified Subgroups
Subgroup analyses were conducted using the same imputed data sets and the same MMRM model as for the primary analysis for each subgroup category, separately. If the subgroup was one of the covariates in the model, the covariate was removed from the model statement when the model was performed for th
Slide 4: Gd-IgA1 Reduction and Hematuria Resolution
Gd-IgA1 Reduction and Hematuria Resolution Mean (95% CI) % Change from Baseline1 97 104 95 101 n= Placebo Atacicept Week 94 100 93 96 93 103 -3% 4 Gd-IgA1 Reduction -68% Δ 67% p<0.0001 Change from Baseline in % Patients with Hematuria (95% CI)2 Week 58 64 58 63 58 64 58 64 -81% -21% Odds ratio 19.1
Slide 5: Adverse Events Generally Balanced Between Groups
Adverse Events Generally Balanced Between Groups Most adverse events were mild or moderate in severity Rate of serious adverse events was lower in the atacicept group compared with placebo No deaths occurred Participants, n (%) Atacicept n=214 Placebo n=214 Adverse events 127 (59) 107 (50) Serious a
Slide 6: Vera Therapeutics
Vera therapeutics™
Vera Therapeutics — Investor Presentation (November 2025) on 6ix